Why Attend
Protein degradation has redefined the drug discovery landscape, offering a promising solution in the quest to ‘drug the undruggable’. Whilst over the past few years this field as witnessed unprecedented growth, investment, and intrigue (around €4 billion worth, to be precise), 2021 is set to be another showstopper for targeted protein degradation with 15 compounds predicted to enter the clinic by the end of the year.
As we enter a new wave of drug discovery:
- Explore the clinical viability of protein degraders including discussions on delivery methods, optimisation strategies and DMPK & SAR parameters
- Learn how multispecifics that form connections between POIs and cellular machinery are expanding drug amenability of proteins in this untapped, new wave of medicine.
- Reach “undruggable” high-hanging fruit using chemoproteomics platforms including DNA encoded libraries and covalent ligand discovery
Poster Submission 2021
Looking to showcase your recent work to the protein degradation community?
Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.
Poster abstract submission deadline is on 17 August 2021. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
If you have any questions please contact [email protected]
Previous Attendees Include
Audience Breakdown
Become a Partner
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
2021 Partners
Expertise Partners
Promega
Website: https://www.promega.com
Promega Corporation is a world leader in providing innovative solutions to the life sciences. We develop bioluminescent technologies that deliver more biologically relevant data for small and large molecule drug discovery. We are the commercial leader in offering sensitive, real-time assays for PROTACs and Protein Degradation. Is my target protein degraded? Is it recruited to the proteasome? Is my PROTAC cell permeable? Speak with a Promega representative to learn how to answer these questions. For more information www.promega.com.
Pelago Bioscience AB
Website: https://www.pelagobio.com/
Pelago Bioscience AB established in 2013 provides and develops the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions, to accelerate drug discovery and diagnostics development. CETSA® provides a quantitative measure of target engagement and the biophysical readout of affinity, and adds real value to existing efficacy assays. We deliver complete target engagement hit confirmation data sets, develop and validate assays for use in screening cascades, and profile candidate drugs based on the CETSA® method, tailored to the project need.
Event Partners
Fluidic Analytics
Website: https://www.fluidic.com/
Fluidic Analytics- Understand the machinery of life
With the right tool, protein researchers can change the world around us.
Our award-winning technologies open doors for scientists to understand proteins and their behavior better than ever before. By characterizing proteins and their interactions, scientists can make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. Our revolutionary technologies give researchers a fundamentally new way to analyze proteins without compromise, because we truly believe the right tools in the right hands will change the world.
Proteome Sciences
Website: https://www.proteomics.com/
Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications.
By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment.
Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples. By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project. Sensitivity is equivalent to conventional ELISA in many cases.
In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM. Proteins selected can be either known previously, or more often detected above via our Discovery Services. We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.
BioTheryX
Website: https://www.biotheryx.com/
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven clinical and commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases. Our lead molecule is currently in Phase I clinical trial for Acute Myeloid Leukemia and high-risk MDS and our lead protein degradation “molecular glue” molecule (Protein Homeostatic Modulator or PHM®) will be in the clinic in 2021 for hematological malignancies.
Aurelia Biosciences
Website: https://www.aureliabio.com/
Aurelia Bioscience is a UK based pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have significant experience of different target classes and use cutting edge technologies to deliver client projects in a timely, efficient and cost-effective manner. They work in early stages of the drug discovery pipeline including target identification and validation, hit identification, hit to lead as well as lead identification and optimisation.
Liverpool ChiroChem
Website: https://www.liverpoolchirochem.com/
Liverpool ChiroChem (LCC) is a chemical technology innovator that produces chiral small molecules for biotech/pharmaceutical R&D. As the Home of Chiral N-Heterocycles, our initial focus is the production and supply of sp3-rich chiral N- heterocycles, readily accessible, chirally pure and available on scale. The harnessed expert synthetic technologies provide efficient access to a variety of novel, compact, chiral building blocks, in order to facilitate access to new chemical space for hit identification and potential further hit expansion. Finally, our proprietary products are ideally suited for DNA-Encoded Library synthesis and Fragment Based Lead Discovery, which many medicinal chemists consider to be the two leading areas of modern-day drug discovery.
Dynamic Biosensors
Website: https://www.dynamic-biosensors.com/
Please visit our website for more information.What attendees say
2021 Speakers
Benedict Cross
Carlotta Cecchini
Christina Woo
Constantine Mitsiades
Daniel Nomura
Dan Nomura is a professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology with Professor John Casida at UC Berkeley and was a postdoctoral fellow at The Scripps Research Institute in chemical physiology with Professor Ben Cravatt before returning to UC Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, the Department of Defense Breakthroughs Award, and the Mark Foundation for Cancer Research INSPIRE award. Research in the Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to discover new disease therapies.
Anthony Slavin
Elmar Wolf
Fu-Sen Liang
Gaoqi Weng
Kristin Riching
Kristin received her Ph.D. in Biomedical Engineering from the University of Wisconsin – Madison, where she studied the structural and mechanical properties of collagen fibre networks and their effects on breast cancer cell migration in invasive ductal carcinoma. She joined Promega in 2014 as a postdoctoral researcher to study the pharmacology of ligand-dependent responses within the ErbB signalling network. Currently, she is a Senior Scientist developing technologies and approaches for live cell characterization of protein degradation and protein interactions within the ubiquitin proteasome pathway.
Laura Itzhaki
Leah Fung
Matthias Brand
Riccardo De Matos Simoes
Sandra Kumper
Sara Pannilunghi
Stina Lundgren
Thomas Hayhow
Tom Stepherd
Yifat Merbl
Yu Rao
Zuzanna Kozicka
I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.
The Agenda
Please complete the from to receive the full agenda for 2021, including information about the key topics being covered, speakers, and why you should attend.
What you can expect from the 2021 congress:
- 200+ participants from leading industry players within big pharma and biotech along with expert academics and service providers.
- An open forum to share the latest in vivo and in vitro data and insights and foster collaboration.
- 20+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
- 3 days of progressing translation of protein degradation probes into safe, effective therapeutics.
Download Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket prices increase in
highlights from previous years
The Virtual Experience
Top 10 benefits
- Tailor Your Agenda
- More Audience Participation
- Improved Audience Visibility
- On-Demand Content
- High Quality Speakers
- More Networking Opportunities
- Save Time & Money
- Increased Content
- More insights
- Business Development Opportunities - Talk to our team to find out out more [email protected].
Platform Preview
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.